Innate Pharma announced the first patient was dosed in its Phase 1/2 multicenter trial, investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma, or NHL.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>